InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,487.03
(
0.25%
)
US TECH 100
19,430.40
(
0.14%
)
Dow Jones
38,834.86
(
0.15%
)
Brent Oil
84.88
(
0.11%
)
Bitcoin
65,056.35
(
-0.13%
)
Post# of 252254
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

vinmantoo

Send PM Follow Ignore
Followers 30
Posts 4124
Boards Moderated 0
Alias Born 07/25/2007

vinmantoo

Re: NP1986 post# 135278

Wednesday, 01/18/2012 1:07:48 PM

Wednesday, January 18, 2012 1:07:48 PM

Post# of 252254
Overall survival is the metric that won approval for Nexavar in HCC, not PFS. Regorafenib appears to be following that pattern, so I think the focus on the small but not statistically significant increase in PFS for Regorafenib is misplaced.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up